When: Forward P/E compression below 25x

Then: Satisfies one leg of 2-of-3 re-entry framework

When: Any two of three triggers (a), (b), or (c) firing

Then: Qualifies for potential re-engagement/upgrade to Overweight

SELL trim to 50 percent of benchmark (lower end of proposed range), with widened stop at 420 or removed entirely, no reload on technicals

• Sizing should lean toward 50% of benchmark rather than 60%, given stacked headwinds: near-term demand softness, 2027 pricing reset, inventory build outrunning revenue growth, and narrowing competitive landscape
• Stop at 400 is too tight for a 1.47 beta stock; 1.5 ATR above market invites whipsaw during normal volatility; conservative stop should be widened to ~420 or removed entirely
• Re-entry must be based on fundamental confirmation (procedure reacceleration, inventory improvement, pricing reset clarity), not MACD crossover or Bollinger breakout
• Fundamentals remain elite: 67% gross margins, 33% operating margins, $5.2B cash, zero debt, record FCF justify maintaining reduced exposure rather than full exit
• Goal is portfolio capital protection for long-term compounding, not maximizing return on this single name

→ vs aggressive: Stop at 400 (3% above current price, ~1.5 ATR) is too tight for a stock that moves 10% in a week on routine news; high probability outcome is whipsaw, selling at 388, getting stopped at 400, then chasing back at 410; this is not conservative risk management

→ vs aggressive: Calling the trim 'asymmetric' is intellectually dishonest; selling at 388 and potentially buying back at 410 on technical confirmation is symmetric at best; genuine asymmetry requires either more conviction (leading to more aggressive trim) or none at all

→ vs aggressive: EU CE Mark and 14M procedure meta-analysis dismissals as 'rounding errors' is overconfident; clinical evidence matters for hospital purchasing committees defending 67% gross margins against ASP compression

→ vs neutral: Holding full benchmark weight with a CFO acknowledging US procedure deceleration, China headwinds, 2027 pricing reset, and 22% inventory build outrunning 18.5% revenue growth is not conservative; it is passive ownership hoping 'quality saves you'

→ vs neutral: Selling cash-secured puts near current levels adds exposure to a name in structural downtrend; elevated IV compensation evaporates on a single headline gap; this is a volatility trade, not conservative income strategy

SELL to trim to 50% of benchmark weight; stop at 405-410; hybrid reload framework requiring 2 of 3 confirmations (technical, fundamental, valuation); sell cash secured puts at 340-320 strikes (12-15% below current); redeploy capital to reduce portfolio beta or add diversifying positions

• Trim direction is correct but sizing should lean to 50% of benchmark at lower end of proposed range
• Current valuation at 31.7x forward earnings does not justify full benchmark weight given stacked headwinds
• Balance sheet quality (5B cash, zero debt, 67% gross margins, record FCF) does not justify full exit either
• EU CE Mark for da Vinci SP gynecology is not a rounding error; first-ever transvaginal use opens new revenue lane in high-volume surgical category
• 14M procedure meta-analysis showing superior outcomes across 13 conditions is fresh evidence for hospital purchasing committees defending premium pricing against 2027 ASP compression
• Stop at 400 is too tight (1.5 ATR) for a beta 1.47 stock that can move 10% in a week; 420 gives back entire trim benefit
• Recommended stop zone 405-410 is just above August 401 highs where buyers previously showed up, roughly 2 ATR above current
• Volatility-adjusted trailing stop is alternative to hard level stop
• Reload framework must be hybrid: reclaim 200 SMA at 456 on above-average volume (technical); two consecutive quarters US procedure reacceleration or China policy resolution (fundamental); forward P/E compression below 25x (valuation)
• Pure technical reload (Bollinger/MACD) is chase-strength trap that will result in buying 10-15% off lows at higher prices
• Pure fundamental reload (waiting for confirmed reacceleration + inventory improvement + pricing clarity) means waiting until stock reclaims 456 and trades to 480+
• Cash secured puts have merit only at strikes 12-15% below current (340 or 320), creating genuine asymmetric payoff; strikes near current are just long exposure in disguise
• Freed capital (1-2% of NAV) should reduce portfolio beta or add diversifying positions, not sit in cash

→ vs aggressive: The 14M procedure meta-analysis and EU CE Mark for da Vinci SP gynecology are dismissed as rounding errors but represent fresh competitive evidence and new revenue lanes respectively; cherry-picking bearish catalysts while discarding bullish ones is motivated reasoning not analysis

→ vs aggressive: Asymmetric payoff framing is incorrect; selling at 388 and buying back at 410 after being stopped at 400 is whipsaw with transaction costs and tax events, not asymmetric upside

→ vs aggressive: Reload on Bollinger upper band break and MACD crossover is literally the chase-strength trap that caused the drawdown being managed; signals fire after stock has already moved 10-15% off lows

→ vs conservative: Widening stop to 420 gives back entire trim benefit since stock is only 9% below that level; not risk management, just hoping to be proven right at a level that may never come

→ vs conservative: Removing stop entirely and substituting fundamental re-entry framework is passive, not conservative; not managing downside at all

→ vs conservative: All-or-nothing dismissal of cash secured puts misses calibrated version (strikes 12-15% below current) that creates genuine asymmetric payoff

→ vs conservative: Re-entry framework requiring confirmed US procedure reacceleration, inventory improvement, and pricing clarity means waiting until stock reclaims 200 SMA at 456 and trades to 480+; not reloading at bottom, reloading after move is over